ALK and anaplastic large cell lymphoma: Routinely, treatment of common ALK+ ALCL includes anthracycline-based regimens, such as CHOP, with approximately 90% response rate.[10] ALK protein positivity indicates excellent prognosis after standard chemotherapy.[11] Although primary cutaneous ALCL tends to relapse in approximately 40% cases, long-term prognosis remains excellent because the relapses are generally cutaneous.